Human CNS-Apolipoprotein E Isoform Production and Clearance A.
Specific Aims : Alzheimer's disease (AD) is a common, devastating disease. 5 million Americans are suffering from AD, and it is currently estimated that by 2050 this number will triple. The only major and wellvalidated genetic risk factor for AD is one's Apolipoprotein E (ApoE) genotype. One ApoE4 allele increases the risk of developing AD by 3-fold, while two copies of ApoE4 increase this risk by 12-fold. A reduced risk for AD is associated with the ApoE2 allele. The metabolism and function of ApoE is partially understood in the periphery, however very little is known about ApoE in the central nervous system (CNS). Because ApoE plays such an important role in the CNS, and because its metabolism in the CNS is not well understood, we propose to determine the physiology and possible isoform pathophysiology as it relates to AD. Isoform dependent changes in ApoE metabolism and amount (and subsequently transport of AP) may underiie the increased risk of AD in humans. Hypothesis 1: ApoE4 amount is less in the brain and CSF vs. ApoE3. Hypothesis 2: ApoE4 clearance rate or turn-over rate if faster in the CNS compared to ApoE3.
Specific Aim : Utilizing a recently developed mass spectrometry assay to measure ApoE isoforms independently, we will measure ApoE4 and ApoE3 in the human brain and CSF. In addition, the in vivo metabolism of human ApoE will be measured using stable isotope-labeling and mass spectrometry in 60 cognitively normal or dementia of the Alzheimer's type (DAT) participants with E2, E3 or E4 ApoE alleles. These participants will be recruited from the Washington University ADRC. B. Relevance to Alzheimer's Disease: ApoE is the strongest genetic risk factor for Alzheimer's disease, and is a potential target for disease-modifying therapies. Our data will provide an important link regarding how ApoE4 may be involved in the pathophysiology of Alzheimer's disease, and may lead to improved therapeutics, which target the major genetic risk factor of Alzheimer's disease, ApoE4.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005681-29
Application #
8441092
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
29
Fiscal Year
2012
Total Cost
$182,451
Indirect Cost
$62,107
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148
Wildburger, Norelle C; Esparza, Thomas J; LeDuc, Richard D et al. (2017) Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. Sci Rep 7:9520
Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528
Roe, Catherine M; Babulal, Ganesh M; Head, Denise M et al. (2017) Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y) 3:74-82
Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189
Miller-Thomas, Michelle M; Benzinger, Tammie L S (2017) Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am 25:297-313
Alosco, Michael L; Duskin, Jonathan; Besser, Lilah M et al. (2017) Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. J Alzheimers Dis 57:953-968
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2017) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord 31:69-72
Pandya, Seema Y; Lacritz, Laura H; Weiner, Myron F et al. (2017) Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. Dement Geriatr Cogn Disord 43:204-214
Lewczuk, Piotr; Matzen, Anja; Blennow, Kaj et al. (2017) Cerebrospinal Fluid A?42/40 Corresponds Better than A?42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis 55:813-822

Showing the most recent 10 out of 825 publications